HIF-2α, at least in some tumors, shows a greater oncogenic capacity than HIF-1α, and its overexpression correlates with poor patient outcome in colorectal carcinoma, melanoma, ovarian cancer, non-small cell lung cancers, and HCC [20,21]. The gene discussed is EPAS1; the disease is non-small cell lung carcinoma.